Buprenorphine for Opioid Dependence

Megan Milne College of Pharmacy, University of Utah, Salt Lake City, Utah, USA

Barbara Insley Crouch College of Pharmacy, University of Utah, Salt Lake City, Utah, USA; Utah Poison Control Center, University of Utah, Salt Lake City, Utah, USACorrespondence[email protected]

E. Martin Caravati Utah Poison Control Center, University of Utah, Salt Lake City, Utah, USA; School of Medicine, University of Utah, Salt Lake City, Utah, USA

Abstract

Buprenorphine is a partial mu agonist opioid that is FDA-approved to manage opioid addiction in settings outside of traditional methadone clinics. The clinical uses, pharmacokinetics, pharmacodynamics, toxicology, and management of overdoses of buprenorphine are reviewed.

KEYWORDS:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Buprenorphine for Opioid Dependence

Information for

Open access

Opportunities

Help and information

Buprenorphine for Opioid Dependence

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature